EnVision Endoscopy has closed an oversubscribed $11.5 million Series A financing and completed its first 50 patient procedures using the SimpleStitch Suturing System. The Waltham, Massachusetts-based medical technology company develops devices designed to expand access to minimally invasive gastrointestinal endoscopic surgery.
FDA-cleared in 2025, SimpleStitch is designed to enable endoscopic suturing and tissue closure using standard flexible endoscopes. The system aims to address challenges associated with closing tissue defects following advanced procedures such as endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), and peroral endoscopic myotomy (POEM). EnVision says the technology is intended to bridge the gap between conventional clips and more advanced suturing systems that require specialized equipment and extensive training.
The first 50 procedures were completed at pilot sites during 2026. According to the company, all were completed safely. The limited U.S. market release began this year.
The Series A round was led by Puma Venture Capital, with participation from UTEC – University of Tokyo Edge Capital, Olympus Corporation of the Americas, and MassVentures. Funding will support commercial expansion, physician training, clinical evidence generation, manufacturing scale-up, and further product development.